These findings suggest miR-128-3p and SIRT1 may serve as new targets for the therapy of CaOx nephrolithiasis, and provide a potential use of TF in oxalate kidney injury, as well as kidney stone formation. This evidence concerns the gene TF and nephrolithiasis.